Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karim Bennaceur is active.

Publication


Featured researches published by Karim Bennaceur.


Journal of Medicinal Chemistry | 2011

Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency

Ian R. Hardcastle; Junfeng Liu; Eric Valeur; Anna Watson; Shafiq U. Ahmed; Timothy J. Blackburn; Karim Bennaceur; William Clegg; Catherine J. Drummond; Jane A. Endicott; Bernard T. Golding; Roger J. Griffin; Jan Gruber; Karen Haggerty; Ross W. Harrington; Claire Hutton; Stuart J. Kemp; Xiaohong Lu; James M. McDonnell; David R. Newell; Martin Noble; Sara L. Payne; Charlotte H. Revill; Christiane Riedinger; Qing Xu; John Lunec

Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors. The isoindolinone scaffold has proved to be versatile for the discovery of MDM2-p53 antagonists. Optimization of previously reported inhibitors, for example, NU8231 (7) and NU8165 (49), was guided by MDM2 NMR titrations, which indicated key areas of the binding interaction to be explored. Variation of the 2-N-benzyl and 3-alkoxy substituents resulted in the identification of 3-(4-chlorophenyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-nitrobenzyl)isoindolin-1-one (74) as a potent MDM2-p53 inhibitor (IC(50) = 0.23 ± 0.01 μM). Resolution of the enantiomers of 74 showed that potent MDM2-p53 activity primarily resided with the (+)-R-enantiomer (74a; IC(50) = 0.17 ± 0.02 μM). The cellular activity of key compounds has been examined in cell lines with defined p53 and MDM2 status. Compound 74a activates p53, MDM2, and p21 transcription in MDM2 amplified cells and shows moderate selectivity for wild-type p53 cell lines in growth inhibition assays.


Physical Review C | 2004

Microscopic determination of the nuclear incompressibility within the nonrelativistic framework

G. Colo; N. Van Giai; J. Meyer; Karim Bennaceur; P. Bonche

The nuclear incompressibility


Biochimica et Biophysica Acta | 2009

Immunosuppressive networks in the tumour environment and their effect in dendritic cells

Karim Bennaceur; Jessica Alice Chapman; Jean-Louis Touraine; Jacques Portoukalian

{K}_{\ensuremath{\infty}}


Clinical Journal of The American Society of Nephrology | 2012

Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?

David J. Kavanagh; Isabel Y. Pappworth; Holly E. Anderson; Christine Hayes; Iain Moore; Eva Maria Hunze; Karim Bennaceur; Pietro Roversi; Susan M. Lea; Lisa Strain; Roy Ward; Nick Plant; Corina Nailescu; Timothy H.J. Goodship; Kevin J. Marchbank

is deduced from measurements of the isoscalar giant monopole resonance (ISGMR) in medium-heavy nuclei, and the resulting value turns out to be model dependent. Since the considered nuclei have neutron excess, it has been suggested that the model dependence is due to the different behavior of the symmetry energy in different models. To clarify this issue, we make a systematic and careful analysis based on new Skyrme forces, which span a wide range of values for


Cancer Letters | 2008

Dendritic cells dysfunction in tumour environment

Karim Bennaceur; Jessica Alice Chapman; Leila Brikci-Nigassa; Kamel Sanhadji; Jean-Louis Touraine; Jacques Portoukalian

{K}_{\ensuremath{\infty}}


Physical Review C | 2009

Tensor part of the Skyrme energy density functional. II: Deformation properties of magic and semi-magic nuclei

M. Bender; Karim Bennaceur; Thomas Duguet; P.-H. Heenen; Thomas Lesinski; Jacques Meyer

, for the value of the symmetry energy at saturation and for its density dependence. By calculating, in a fully self-consistent fashion, the ISGMR centroid energy in


Physical Review C | 2006

Isovector splitting of nucleon effective masses, ab initio benchmarks and extended stability criteria for Skyrme energy functionals

Thomas Lesinski; Karim Bennaceur; Thomas Duguet; J. Meyer

^{208}\mathrm{Pb}


Journal of Clinical Investigation | 2015

T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients

Stephen Boag; Rajiv Das; Evgeniya V. Shmeleva; Alan Bagnall; Mohaned Egred; Nicholas Howard; Karim Bennaceur; Azfar Zaman; Bernard Keavney; Ioakim Spyridopoulos

, we reach three important conclusions: (i) the monopole energy, and consequently the deduced value of


Bioorganic & Medicinal Chemistry Letters | 2011

MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.

Anna Watson; Junfeng Liu; Karim Bennaceur; Catherine J. Drummond; Jane A. Endicott; Bernard T. Golding; Roger J. Griffin; Karen Haggerty; Xiaohong Lu; James M. McDonnell; David R. Newell; Martin Noble; Charlotte H. Revill; Christiane Riedinger; Qing Xu; Yan Zhao; John Lunec; Ian R. Hardcastle

{K}_{\ensuremath{\infty}}


Glycobiology | 2009

Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells

Karim Bennaceur; Iuliana Popa; Jessica Alice Chapman; Camille Migdal; Josette Péguet-Navarro; Jean-Louis Touraine; Jacques Portoukalian

, depend on a well-defined parameter related to the shape of the symmetry energy curve and called

Collaboration


Dive into the Karim Bennaceur's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas Duguet

Michigan State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Bender

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge